TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lyra Therapeutics ( (LYRA) ) has provided an update.
On September 4, 2025, Lyra Therapeutics announced the posting of a corporate presentation on their website, detailing their progress and future plans for LYR-210, a drug implant for chronic rhinosinusitis. The presentation highlighted the company’s recent achievements, including the successful completion of the ENLIGHTEN 2 Phase 3 trial, and outlined the regulatory path forward for LYR-210, which has shown promising results in both polyp and non-polyp CRS populations. Despite past challenges, such as the failure of the ENLIGHTEN 1 trial and financial difficulties, Lyra is focused on advancing LYR-210 towards approval and addressing the large unmet need in the CRS market.
The most recent analyst rating on (LYRA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.
Spark’s Take on LYRA Stock
According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.
Lyra Therapeutics faces significant financial and valuation challenges, with ongoing losses and a negative P/E ratio. The stock’s technical indicators suggest a bearish trend. While recent clinical trial successes and strategic plans offer some hope, the risk of Nasdaq delisting due to financial instability is a critical concern.
To see Spark’s full report on LYRA stock, click here.
More about Lyra Therapeutics
Lyra Therapeutics is a late-stage biotechnology company specializing in the development of long-acting, bioabsorbable, anti-inflammatory sinonasal drug implants for the treatment of chronic rhinosinusitis (CRS). Their primary product, LYR-210, targets both polyp and non-polyp CRS populations, addressing a significant unmet need in a multi-billion dollar market.
Average Trading Volume: 110,862
Technical Sentiment Signal: Sell
Current Market Cap: $12.19M
For a thorough assessment of LYRA stock, go to TipRanks’ Stock Analysis page.